Abstract
Objective: Based on clinical studies for two approved vesicular monoamine transporter 2 (VMAT2) inhibitors (valbenazine, deutetrabenazine), these medications are recommended as first-line therapies for tardive dyskinesia (TD). Real-world data for these drugs are now available. The objective of this study was to describe symptom impact and treatment outcomes in patients prescribed VMAT2 inhibitors for the treatment of TD.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
